ReviewThe Lancet regional health. Europe2026

Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab.

Lorenzo Guizzaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.